Chronic illness drug developer Sigilon Therapeutics, co-founded by MIT and UIC researchers, has filed to go public after raising almost $200m in funding.

Sigilon¬†Therapeutics, a US-based chronic illness therapy developer based on research primarily from Massachusetts Institute of Technology (MIT), has filed for a $100m initial public offering on the Nasdaq Global Market. Founded in 2015, Sigilon has built a drug development platform dubbed Shielded Living Therapeutics which it is using to create therapeutic molecules that can make…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.